Consolidated statements of income and comprehensive income
(unaudited)
|
Third quarter of |
Nine months ended 30 September |
||
(thousands of €, except share and per share data) |
2018 |
2017 |
2018 |
2017 |
Revenues |
94,874 |
26,945 |
182,457 |
87,870 |
Other income |
8,334 |
6,378 |
22,623 |
18,484 |
Total revenues and other income |
103,208 |
33,323 |
205,080 |
106,354 |
|
|
|
|
|
Research and development expenses |
(80,314) |
(56,313) |
(231,758) |
(149,226) |
General and administrative expenses |
(9,725) |
(5,853) |
(24,925) |
(17,783) |
Sales and marketing expenses |
(898) |
(808) |
(1,912) |
(1,898) |
Total operating expenses |
(90,937) |
(62,974) |
(258,595) |
(168,907) |
|
|
|
|
|
Operating gain / loss (–) |
12,271 |
(29,651) |
(53,515) |
(62,552) |
|
|
|
|
|
Financial income |
2,558 |
1,344 |
10,667 |
3,663 |
Financial expenses |
(467) |
(8,232) |
(1,708) |
(26,805) |
|
|
|
|
|
Gain / loss (–) before tax |
14,362 |
(36,539) |
(44,557) |
(85,694) |
|
|
|
|
|
Income taxes |
480 |
(69) |
343 |
(161) |
|
|
|
|
|
Net gain / loss (–) |
14,841 |
(36,608) |
(44,215) |
(85,855) |
Net gain / loss (–) attributable to: |
|
|
|
|
Owners of the parent |
14,841 |
(36,608) |
(44,215) |
(85,855) |
Basic gain / loss (–) per share |
0.29 |
(0.73) |
(0.86) |
(1.75) |
Diluted gain / loss (–) per share |
0.28 |
(0.73) |
(0.86) |
(1.75) |
The accompanying notes form an integral part of these condensed consolidated financial statements.
|
Third quarter of |
Nine months ended 30 September |
||
(thousands of €) |
2018 |
2017 |
2018 |
2017 |
Net gain / loss (–) |
14,841 |
(36,608) |
(44,215) |
(85,855) |
Items that may be reclassified subsequently to profit or loss: |
|
|
|
|
Fair value adjustment of available-for-sale financial assets |
– |
(253) |
– |
(62) |
Translation differences, arisen from translating foreign activities |
5 |
(253) |
156 |
(569) |
Other comprehensive income / loss (–), net of income tax |
5 |
(506) |
156 |
(631) |
|
|
|
|
|
Total comprehensive income / loss (–) attributable to: |
|
|
|
|
Owners of the parent |
14,846 |
(37,114) |
(44,059) |
(86,486) |
The accompanying notes form an integral part of these condensed consolidated financial statements.